Surprisingly, a study by Nie W et al. in 2020 showed that NSCLC patients with low TMB may because of significantly higher levels of Th1 and Th17 cells more suitable anti-PD-1/PD-L1 immunotherapy [45]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.